Q3 2024 Dyadic International Inc Earnings Call Transcript

Nov 12, 2024 / 10:00 PM GMT

Release Date Price: $1.14 (+8.57%)

Transcript 8-K10-Q

Key Points

Positve

Dyadic International Inc (DYAI) reported a significant increase in revenue for Q3 2024, reaching approximately $1,958,000 compared to $397,000 for the same period a year ago.
The company has successfully achieved multiple revenue streams through licensing agreements and milestone payments, including a $1 million license revenue from Proliant and a $425,000 success fee.
Dyadic's proprietary C1 and DPAAS platforms are showing promising results in producing recombinant proteins and enzymes, which are crucial for various applications in health, nutrition, and wellness.
The company is actively collaborating with top pharmaceutical companies and biotech firms, advancing projects in infectious disease vaccines and antibodies, which could lead to significant future growth.
Dyadic is strategically positioned to capitalize on the growing demand for alternative proteins and biopharmaceuticals, with a focus on high-value markets such as cell culture media and animal-free dairy products.

Negative

Despite the revenue growth, Dyadic International Inc (DYAI) reported a net loss of $203,000 for Q3 2024, although this is an improvement from the $1,614,000 loss in the same period last year.
Research and development expenses decreased, reflecting a winding down of activities related to the company's phase one clinical trial, which may indicate a slowdown in new internal research projects.
The company faces high production costs for animal-free dairy products, which could impact profitability unless efficiencies are improved.
There is a dependency on collaborations and partnerships for revenue generation, which may pose risks if any partnerships do not yield expected results.
The market for recombinant proteins and enzymes is competitive, and Dyadic must continue to innovate and improve productivity to maintain its market position.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

DYAI.OQ - Dyadic International Inc
Q3 2024 Dyadic International Inc Earnings Call
Nov 12, 2024 / 10:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good evening and welcome to Dii International Q3 2024 conference call. Currently all participants are in a listen-only mode following management's prepared remarks. There will be a brief question and answer session as a reminder, this conference call is being recorded today. November 12th 2024. I would now like to turn the call over to MS Ping Rawson Dii, Chief Financial Officer. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you. Good evening and welcome everyone to Dii International's Q3 2024 conference call. I hope you have had an opportunity to

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.